Dr Kieran Docherty

Clinical Senior Lecturer with Interest in Heart Failure & Clinical Trial (Cardiovascular & Metabolic Health)

email: Kieran.Docherty@glasgow.ac.uk

BHF Cardiovascular Research Centre, 126 University Place, Glasgow, G12 8TA

Biography

Kieran Docherty is Clinical Lecturer in Cardiology in the School of Cardiovascular and Metabolic Health at the University of Glasgow and an Honorary Specialist Registrar in Cardiology at Glasgow Royal Infirmary, Glasgow, UK.

He completed his PhD under the supervision of Professor John McMurray and Professor Mark Petrie examining the effect of neprilysin inhibition on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction (RECOVER-LV - NCT03552575). He is Co-PI of the EMPRESS-MI trial (NCT05020704) studying the effect of SGLT2 inhibition in acute myocardial infarction in patients at high risk of developing heart failure. He is PI of the TARTAN-HF trial (NCT05705869) examining the potential benefits of a targeted natriuretic peptide-based screening strategy in patients with diabetes and risk factors for heart failure.

Dr Docherty is a Fellow of the European Society of Cardiology (ESC). He was awarded the Young Clinical Investigator Award at the ESC Heart Failure Association Congress in 2022 and is a Cardiovascular Clinical Trialist’s (CVCT) Forum Future Clinical Trialist Fellow. He has co-authored over 100 publications in journals such as the New England Journal of Medicine, the Lancet and JAMA, and is the author of two chapters in the ESC Textbook of Cardiovascular Medicine.

Research interests

Research Theme: Cardiac Diseases

Research interests include mechanisms and treatment of cardiovascular disease with a focus on heart failure. His research includes clinical trials in cardiovascular disease with a particular interest in evaluating the effects of drugs on left ventricular remodelling in patients with heart failure and following acute myocardial infarction.

Research groups

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013

Number of items: 124.

2024

Docherty, K. F. et al. (2024) Interleukin-6 in HFrEF and the effect of dapagliflozin: an exploratory analysis of DAPA-HF. JACC: Heart Failure, (Accepted for Publication)

Carberry, J. et al. (2024) Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). European Journal of Heart Failure, (doi: 10.1002/ejhf.3560) (Early Online Publication)

Docherty, K. F. et al. (2024) Wearable accelerometer-derived measures of physical activity in heart failure: insights from the DETERMINE trials. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2024.10.439) (PMID:39603408) (In Press)

Osmanska, J., Petrie, M. C. , Docherty, K. F. , Lee, M. M.Y. , McMurray, J. J.V. and Campbell, R. (2024) Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal: Cardiovascular Pharmacotherapy, (doi: 10.1093/ehjcvp/pvae083) (Accepted for Publication)

Butt, J. H., Shen, L., Inzucchi, S. E., Docherty, K. F. , Jhund, P. S. , Martinez, F. A., Sabatine, M. S., Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2024) Dapagliflozin in heart failure, type 2 diabetes, and neuropathy. JACC: Heart Failure, 12(11), pp. 1946-1948. (doi: 10.1016/j.jchf.2024.07.017) (PMID:39269393)

Docherty, K. F. et al. (2024) Effect of dapagliflozin on accelerometer-based measures of physical activity in patients with heart failure: an analysis of the DETERMINE trials. Circulation: Heart Failure, 17(10), e012349. (doi: 10.1161/CIRCHEARTFAILURE.124.012349) (PMID:39212948) (PMCID:PMC11472896)

Doherty, D. J., Abdin, A. and Docherty, K. F. (2024) Heart failure medical therapy in the last years of life: prognosis and practicalities. European Journal of Heart Failure, (doi: 10.1002/ejhf.3450) (PMID:39225181) (Early Online Publication)

Butt, J. et al. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 12(9), pp. 1586-1599. (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262)

Ryan, M. et al. (2024) Effect of PCI on health status in ischemic left ventricular dysfunction: insights from REVIVED-BCIS2. JACC: Heart Failure, 12(9), pp. 1553-1562. (doi: 10.1016/j.jchf.2024.03.010) (PMID:38727649)

Cameron, A. et al. (2024) Natriuretic peptides to classify risk of atrial fibrillation detection after stroke: analysis of the BIOSIGNAL and PRECISE cohort studies. Neurology, 103(3), e209625. (doi: 10.1212/WNL.0000000000209625) (PMID:38950311) (PMCID:PMC11226326)

Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Carberry, J., Marquis-Gravel, G., O’Meara, E. and Docherty, K. F. (2024) Where are we with treatment and prevention of heart failure in patients post myocardial infarction? JACC: Heart Failure, 12(7), pp. 1157-1165. (doi: 10.1016/j.jchf.2024.04.025) (PMID:38878010)

Espersen, C. et al. (2024) Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure. International Journal of Cardiology, 406, 132036. (doi: 10.1016/j.ijcard.2024.132036) (PMID:38599465)

Yang, M. et al. (2024) Dapagliflozin and quality of life measured using the EuroQol 5-Dimension questionnaire in patients with HFrEF and HFmrEF/HFpEF. European Journal of Heart Failure, 26(7), pp. 1524-1538. (doi: 10.1002/ejhf.3263) (PMID:38700986)

Traub, J., Docherty, K. F. and Frey, A. (2024) The link between heart failure and neurodegeneration insights from circulating biomarkers. JACC: Heart Failure, 12(6), pp. 1086-1088. (doi: 10.1016/j.jchf.2024.04.008) (PMID:38839152)

Kondo, T. et al. (2024) Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF. Journal of the American College of Cardiology, 83(20), pp. 1973-1986. (doi: 10.1016/j.jacc.2024.03.385) (PMID:38537918)

Lassen, M. C. H. et al. (2024) Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: a pre‐specified analysis of the DELIVER trial. European Journal of Heart Failure, 26(7), pp. 1539-1548. (doi: 10.1002/ejhf.3269) (PMID:38745498)

McDowell, K. et al. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)

Buendia, R., Karpefors, M., Folkvaljon, F., Hunter, R., Sillen, H., Luu, L., Docherty, K. and Cowie, M. R. (2024) Wearable sensors to monitor physical activity in heart failure clinical trials: state-of-the-art review. Journal of Cardiac Failure, 30(5), pp. 703-716. (doi: 10.1016/j.cardfail.2024.01.016) (PMID:38452999)

Brum, W. S., Docherty, K. F. , Ashton, N. J., Zetterberg, H., Hansson, O., McMurray, J. J. V. and Blennow, K. (2024) Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurology, 81(2), pp. 197-200. (doi: 10.1001/jamaneurol.2023.4719) (PMID:38109077) (PMCID:PMC10728797)

Docherty, K. F. et al. (2024) The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, 30(1), pp. 26-35. (doi: 10.1016/j.cardfail.2023.08.020) (PMID:37683911)

Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)

2023

McMurray, J. J.V. et al. (2023) Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation, (doi: 10.1161/CIRCULATIONAHA.123.065061) (PMID:38059368) (Early Online Publication)

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)

Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)

Chatur, S. et al. (2023) Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation, 148(22), pp. 1735-1745. (doi: 10.1161/circulationaha.123.066506) (PMID:37632455) (PMCID:PMC10664793)

Mc Causland, F. R. et al. (2023) Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiology, 9(2), pp. 144-152. (doi: 10.1001/jamacardio.2023.4664) (PMID:37952176) (PMCID:PMC10641768)

Docherty, K. F. (2023) SGLT2 inhibitors and iron: more than meets the eye. JACC: Heart Failure, 11(11), pp. 1623-1625. (doi: 10.1016/j.jchf.2023.08.013) (PMID:37737759)

Heerspink, H. J. L. et al. (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25(11), pp. 3327-3336. (doi: 10.1111/dom.15232) (PMID:37580309)

Butt, J. et al. (2023) Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11(10), pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016) (PMID:37318419)

Lam, C. S.P., Docherty, K. F. , Ho, J. E., McMurray, J. J.V. , Myhre, P. L. and Omland, T. (2023) Recent successes in heart failure treatment. Nature Medicine, 29(10), pp. 2424-2437. (doi: 10.1038/s41591-023-02567-2) (PMID:37814060)

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, 25(8), pp. 1364-1371. (doi: 10.1002/ejhf.2912) (PMID:37210608)

Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)

Docherty, K. F. , Lam, C. S.P., Rakisheva, A., Coats, A. J.S., Greenhalgh, T., Metra, M., Petrie, M. C. and Rosano, G. M.C. (2023) Heart failure diagnosis in the general community - who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25(8), pp. 1185-1198. (doi: 10.1002/ejhf.2946) (PMID:37368511)

Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)

Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)

Talha, K. M. et al. (2023) Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, 25(7), pp. 999-1009. (doi: 10.1002/ejhf.2864) (PMID:37062865)

Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)

Campbell, R. T. and Docherty, K. F. (2023) Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance? European Heart Journal, 44(22), pp. 2006-2008. (doi: 10.1093/eurheartj/ehad209) (PMID:37160825)

Yeoh, S. E. et al. (2023) Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147(22), pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327) (PMID:37039015) (PMCID:PMC10212584)

Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)

Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)

Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)

Docherty, K. F. and Jhund, P. S. (2023) A welcome ‘failure’ of gliflozins: blood pressure reduction in heart failure. European Heart Journal, 44(5), pp. 408-410. (doi: 10.1093/eurheartj/ehac712) (PMID:36514970)

Docherty, K. F. et al. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)

Lee, M. M.Y. , Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F. , Lindner, M., Liu, J., Solomon, S. D., McMurray, J. J.V. and Platz, E. (2023) Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25(1), pp. 54-60. (doi: 10.1002/ejhf.2699) (PMID:36161429) (PMCID:PMC9892176)

Mc Causland, F. R. et al. (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(1), pp. 56-65. (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)

2022

Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)

Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)

Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)

Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)

Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Lewis, G. D. et al. (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA: Journal of the American Medical Association, 328(3), pp. 259-269. (doi: 10.1001/jama.2022.11016) (PMID:35852527)

Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

McDowell, K. and Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847) (PMID:35789017) (PMCID:PMC9254667)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)

Lee, M. M.Y. , Docherty, K. F. and Jhund, P. S. (2022) Sodium–glucose co-transporter-2 inhibitors. In: Clark, A. L., Gardner, R. S. and McDonagh, T. A. (eds.) Oxford Textbook of Heart Failure (2 edn). Oxford University Press, pp. 637-644. ISBN 9780198766223 (doi: 10.1093/med/9780198766223.003.0051)

Lewis, G. D. et al. (2022) Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circulation: Heart Failure, 15(5), e008970. (doi: 10.1161/CIRCHEARTFAILURE.121.008970) (PMID:35236099)

Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004) (PMID:36339117) (PMCID:PMC9627879)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)

Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)

Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)

2021

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300) (PMID:33709520) (PMCID:PMC8120385)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)

McMurray, J. J.V. , Solomon, S. D., Docherty, K. F. and Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)

Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)

Docherty, K. F. and Vaduganathan, M. (2021) OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 23(1), pp. 136-139. (doi: 10.1002/ejhf.2106) (PMID:33480140)

McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)

2020

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)

Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)

McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)

Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)

Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)

Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)

Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)

2019

McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)

Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)

Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)

Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)

Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)

2018

Docherty, K. F. and Jhund, P. S. (2018) Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early? Heart, 104(22), pp. 1812-1813. (doi: 10.1136/heartjnl-2018-313371) (PMID:29760244)

Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)

2017

Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)

2016

Wilson, M. R. , Docherty, K. F. and Gardner, R. S. (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber, 27(8), pp. 15-22. (doi: 10.1002/psb.1487)

2014

Docherty, K. F. and Padmanabhan, S. (2014) Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 715-746. ISBN 9780123868831 (doi: 10.1016/B978-0-12-386882-4.00031-1)

2013

Vuorio, A., Docherty, K.F. , Humphries, S.E., Kuoppala, J. and Kovanen, P.T. (2013) Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 226(2), pp. 315-320. (doi: 10.1016/j.atherosclerosis.2012.10.032)

This list was generated on Sun Dec 22 00:40:59 2024 GMT.

Jump to: Articles | Book Sections | Conference or Workshop Item